Cash, cash equivalents and marketable securities totaled $16.9M as of March 31 compared with $23.2M as of December 31, 2024. Unity believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the fourth quarter of 2025. “The 24-week data indicates that UBX1325, acting via a novel mechanism of action, can lead to vision improvement in patients with inadequate response to standard of care,” said Anirvan Ghosh, chief executive officer of Unity. “The full 36-week data will be instrumental in shaping our plans for subsequent studies.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
- Unity Biotechnology price target lowered to $4 from $6 at Chardan
- Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study
- Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
- Unity Biotechnology Appoints Dr. Yehia Hashad to Board